AIM ImmunoTech Inc. announces a registered direct offering and private placement, raising approximately $2.4 million. The company plans to use the funds for drug supply, clinical trials, and working capital.
AIM ImmunoTech Inc. has entered into agreements for a registered direct offering of 7,519,351 shares of common stock at $0.325 per share, expected to raise around $2.4 million. The company also plans a concurrent private placement of Series I warrants. Ladenburg Thalmann & Co
Company Information
Company
AIM ImmunoTech
Location
Ocala, Florida, United States
About
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
Fundz sees it the moment AIM ImmunoTech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
OcalaBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical